Basilea Pharmaceutica Ltd (BPMUF)
44.45
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
Basilea Pharmaceutica Debt to Equity Ratio: -11.09 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | -11.09 |
| June 30, 2023 | 10.08 |
| December 31, 2022 | -8.150 |
| June 30, 2022 | -3.156 |
| December 31, 2021 | -3.720 |
| June 30, 2021 | -2.894 |
| December 31, 2020 | -2.349 |
| June 30, 2020 | -2.490 |
| December 31, 2019 | -2.127 |
| June 30, 2019 | -2.468 |
| December 31, 2018 | -2.954 |
| June 30, 2018 | -3.377 |
| December 31, 2017 | -4.735 |
| June 30, 2017 | -3.866 |
| December 31, 2016 | -5.585 |
| Date | Value |
|---|---|
| June 30, 2016 | -21.75 |
| December 31, 2015 | 13.11 |
| June 30, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| June 30, 2013 | 0.00 |
| December 31, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| December 31, 2011 | 0.00 |
| June 30, 2011 | 0.00 |
| December 31, 2010 | 0.00 |
| June 30, 2010 | 0.00 |
| December 31, 2009 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-11.09
Minimum
Dec 2023
10.08
Maximum
Jun 2023
-2.836
Average
-2.692
Median
Debt to Equity Ratio Benchmarks
| AC Immune SA | 0.00 |
| CRISPR Therapeutics AG | 0.00 |
| Addex Therapeutics Ltd | 0.00 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 206.31M |
| Total Liabilities (Quarterly) | 218.22M |
| Shareholders Equity (Quarterly) | -11.91M |
| Current Ratio | 3.197 |
| Net Debt Paydown Yield | 6.10% |